- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05843162
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome (PRISTINE)
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Soo Lee, MD
- Phone Number: 82-31-787-7035
- Email: limsoo@snu.ac.kr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
[Screening/Run-in period (Visit 1)]
- Adults over 19 years of age
- Patients who have been diagnosed with essential hypertension or who are taking antihypertensive drugs after diagnosis (However, if you are already taking antihypertensive drugs, you can discontinue/change the antihypertensive drugs and agree to this)
- At the time of screening/introduction (Visit 1), the following metabolic syndrome diagnosis criteria ①~④ satisfy ① fasting blood glucose standards, and those who meet at least one of ②~④ criteria (① Fasting blood sugar: ≥100 mg/dL or a state in which medication is being administered to control blood sugar, ② Waist circumference: male ≥90 cm, female ≥85 cm, ③ HDL-cholesterol: male <40 mg/dL, female <50 mg/dL or taking medication to increase HDL-cholesterol, ④ Triglyceride: ≥150 mg/dL or taking medication to lower triglyceride)
[Randomization (Visit 2)]
Patients whose average sitting systolic or diastolic blood pressure measured in the arm selected as the reference arm during the screening test at the time of randomization (Visit 2) corresponds to the following
- 140 mmHg ≤ mean sitting systolic blood pressure (MSSBP) < 180 mmHg
- 90 mmHg ≤ mean sitting diastolic blood pressure (MSDBP) < 110 mmHg
- At the time of randomization (Visit 2), the following metabolic syndrome diagnosis criteria ① to ④ satisfy ① fasting blood sugar criteria, and those who meet at least one of ② to ④ criteria (① Fasting blood sugar: ≥100 mg/dL or a state in which medication is being administered to control blood sugar, ② Waist circumference: male ≥90 cm, female ≥85 cm, ③ HDL-cholesterol: male <40 mg/dL, female <50 mg/dL or taking medication to increase HDL-cholesterol, ④ Triglyceride: ≥150 mg/dL or taking medication to lower triglyceride)
Exclusion Criteria:
Patients whose blood pressure measured at the time of screening/introduction (Visit 1) corresponds to any of the following
- Patients with MSSBP ≥180 mmHg or MSDBP ≥110 mmHg
- Patients with MSSBP ≥20 mmHg and MSDBP ≥10 mmHg difference in blood pressure measured 3 times in each arm
- Patients with a history of secondary hypertension or suspected secondary hypertension (aortic coarctation, hyperaldosteronemia, renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.)
- Patients with orthostatic hypotension with symptoms
- Patients with type 1 diabetes or poorly controlled diabetes (HbA1c >9.0%)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telmisartan
Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab.
2.5mg
|
Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks.
However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study).
However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
|
Active Comparator: Losartan
Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab.
2.5mg
|
Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks.
However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study).
However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MSSBP change
Time Frame: Baseline (Visit 2), 12 weeks (Visit 4)
|
MSSBP change between administration groups after 12 weeks (Visit 4) compared to baseline (Visit 2)
|
Baseline (Visit 2), 12 weeks (Visit 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MSSBP change
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3)
|
MSSBP change between administration groups after 6 weeks (Visit 3) compared to baseline (Visit 2)
|
Baseline (Visit 2), 6 weeks (Visit 3)
|
MSDBP change
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
MSDBP change between administration groups compared to baseline (Visit 2) after 6 weeks (Visit 3) and 12 weeks (Visit 4)
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Blood pressure normalization ratio
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Blood pressure normalization ratio (ratio of subjects with MSSBP <140 mmHg and MSDBP <90 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Blood pressure response rate
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Blood pressure response rate (MSSBP reduction ≥20 mmHg and MSDBP reduction ≥10 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between treatment groups
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HOMA-IR
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HOMA-IR[(Fasting insulin(mU/L)×Fasting glucose(nmol/L))/22.5]
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HOMA-β
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HOMA-β[(20×Fasting insulin(mU/L))/(Fasting glucose(nmol/L)-3.5)]
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in Glucose
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in Glucose(nmol/L)
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in Insulin
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in Insulin(mU/L) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HbA1c
Time Frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Changes in HbA1c (%) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
|
Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Soo MD, MD, Seoul National University Bundang Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Disease
- Insulin Resistance
- Hyperinsulinism
- Hypertension
- Syndrome
- Metabolic Syndrome
- Essential Hypertension
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
- Telmisartan
Other Study ID Numbers
- B115_01HT/MS2201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Telmisartan
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetic NephropathiesJapan
-
Boehringer IngelheimCompleted
-
Laboratorio Elea Phoenix S.A.Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBACompleted